149 related articles for article (PubMed ID: 38450191)
21. Nonpredominant lepidic pattern correlates with better outcome in invasive lung adenocarcinoma.
Mäkinen JM; Laitakari K; Johnson S; Mäkitaro R; Bloigu R; Lappi-Blanco E; Kaarteenaho R
Lung Cancer; 2015 Dec; 90(3):568-74. PubMed ID: 26506915
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact according to the proportion of the lepidic subtype in stage IA acinar-predominant lung adenocarcinoma.
Jeon HW; Kim YD; Sim SB; Moon MH
Thorac Cancer; 2021 Jul; 12(14):2072-2077. PubMed ID: 34033216
[TBL] [Abstract][Full Text] [Related]
23. Identification of three immune subtypes characterized by distinct tumor immune microenvironment and therapeutic response in stomach adenocarcinoma.
Zhu Y; Zhao Y; Cao Z; Chen Z; Pan W
Gene; 2022 Apr; 818():146177. PubMed ID: 35065254
[TBL] [Abstract][Full Text] [Related]
24. Lymph node involvement according to lung adenocarcinoma subtypes: lymph node involvement is influenced by lung adenocarcinoma subtypes.
Park JK; Kim JJ; Moon SW; Lee KY
J Thorac Dis; 2017 Oct; 9(10):3903-3910. PubMed ID: 29268400
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Effects of Predominant Histologic Subtypes in Resected Pulmonary Adenocarcinomas.
Yaldız D; Örs Kaya Ş; Ceylan KC; Acar A; Aydoğdu Z; Gürsoy S; Yaldız S
Balkan Med J; 2019 Oct; 36(6):347-353. PubMed ID: 31525846
[TBL] [Abstract][Full Text] [Related]
26. Histological subtypes of solitary pulmonary nodules of adenocarcinoma and their clinical relevance.
Hu HD; Wan MY; Xu CH; Zhan P; Zou J; Zhang QQ; Zhang YQ
J Thorac Dis; 2013 Dec; 5(6):841-6. PubMed ID: 24409363
[TBL] [Abstract][Full Text] [Related]
27. Minor histological components predict the recurrence of patients with resected stage I acinar- or papillary-predominant lung adenocarcinoma.
Liu W; Zhang Q; Zhang T; Li L; Xu C
Front Oncol; 2022; 12():1090544. PubMed ID: 36620572
[TBL] [Abstract][Full Text] [Related]
28. Solid predominant histologic subtype and early recurrence predict poor postrecurrence survival in patients with stage I lung adenocarcinoma.
Luo J; Wang R; Han B; Zhang J; Zhao H; Fang W; Luo Q; Yang J; Yang Y; Zhu L; Chen T; Cheng X; Huang Q; Wang Y; Zheng J; Chen H
Oncotarget; 2017 Jan; 8(4):7050-7058. PubMed ID: 27732964
[TBL] [Abstract][Full Text] [Related]
29. [The correlation between metabolic parameters in (18)F-FDG PET-CT and solid and micropapillary histological subtypes in lung adenocarcinoma].
Guo Y; Yao ZM; Chen M; Chen CX
Zhonghua Zhong Liu Za Zhi; 2022 Jun; 44(6):555-561. PubMed ID: 35754230
[No Abstract] [Full Text] [Related]
30. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
Yoshida T; Ishii G; Goto K; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Nagai K; Ohe Y; Ochiai A
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1691-700. PubMed ID: 23974272
[TBL] [Abstract][Full Text] [Related]
31. Comparison of small biopsy and cytology specimens: Subtyping of pulmonary adenocarcinoma.
Ma C; Zhang L
Cytojournal; 2023; 20():5. PubMed ID: 36895259
[TBL] [Abstract][Full Text] [Related]
32. Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis.
Zhao Y; Wang R; Shen X; Pan Y; Cheng C; Li Y; Shen L; Zhang Y; Li H; Zheng D; Ye T; Zheng S; Sun Y; Chen H
Ann Surg Oncol; 2016 Jun; 23(6):2099-105. PubMed ID: 26842488
[TBL] [Abstract][Full Text] [Related]
33. Identification of Master Regulators Driving Disease Progression, Relapse, and Drug Resistance in Lung Adenocarcinoma.
Xu Q; Cha Q; Qin H; Liu B; Wu X; Shi J
Front Bioinform; 2022; 2():813960. PubMed ID: 36304306
[No Abstract] [Full Text] [Related]
34. Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma.
Guo Z; Yi F; Yin W; Zhang Y; Li Q; Gu Y; Xiao Y; Cao B; Ma L; Liang L
Thorac Cancer; 2017 May; 8(3):159-169. PubMed ID: 28220630
[TBL] [Abstract][Full Text] [Related]
35. Expression of SARS-COV-2 cell receptor gene ACE2 is associated with immunosuppression and metabolic reprogramming in lung adenocarcinoma based on bioinformatics analyses of gene expression profiles.
Uddin MN; Akter R; Li M; Abdelrahman Z
Chem Biol Interact; 2021 Feb; 335():109370. PubMed ID: 33422520
[TBL] [Abstract][Full Text] [Related]
36. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification.
Russell PA; Wainer Z; Wright GM; Daniels M; Conron M; Williams RA
J Thorac Oncol; 2011 Sep; 6(9):1496-504. PubMed ID: 21642859
[TBL] [Abstract][Full Text] [Related]
37. Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic.
Hasankhani A; Bahrami A; Sheybani N; Aria B; Hemati B; Fatehi F; Ghaem Maghami Farahani H; Javanmard G; Rezaee M; Kastelic JP; Barkema HW
Front Immunol; 2021; 12():789317. PubMed ID: 34975885
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive analysis of diabetic nephropathy expression profile based on weighted gene co-expression network analysis algorithm.
Gholaminejad A; Fathalipour M; Roointan A
BMC Nephrol; 2021 Jul; 22(1):245. PubMed ID: 34215202
[TBL] [Abstract][Full Text] [Related]
39. The difference in Ezrin-pAkt signaling axis between lepidic and papillary predominant invasive adenocarcinomas of the lung.
Hata K; Yoshida J; Udagawa H; Hashimoto H; Fujii S; Hishida T; Kuwata T; Aokage K; Kojima M; Ochiai A; Suzuki K; Tsuboi M; Ishii G
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1421-30. PubMed ID: 27059464
[TBL] [Abstract][Full Text] [Related]
40. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
